The t-N-methyl-d-aspartate receptor: Making the case for d-Serine to be considered its inverse co-agonist.

GluN3 Inverse co-agonist Temporal lobe epilepsy Triheteromeric NMDA receptors d-serine

Journal

Neuropharmacology
ISSN: 1873-7064
Titre abrégé: Neuropharmacology
Pays: England
ID NLM: 0236217

Informations de publication

Date de publication:
01 11 2023
Historique:
received: 27 04 2023
revised: 22 06 2023
accepted: 06 07 2023
medline: 7 8 2023
pubmed: 13 7 2023
entrez: 12 7 2023
Statut: ppublish

Résumé

The N-methyl-d-aspartate receptor (NMDAR) is an enigmatic macromolecule that has garnered a good deal of attention on account of its involvement in the cellular processes that underlie learning and memory, following its discovery in the mid twentieth century (Baudry and Davis, 1991). Yet, despite advances in knowledge about its function, there remains much more to be uncovered regarding the receptor's biophysical properties, subunit composition, and role in CNS physiology and pathophysiology. The motivation for this review stems from the need for synthesizing new information gathered about these receptors that sheds light on their role in synaptic plasticity and their dichotomous relationship with the amino acid d-serine through which they influence the pathogenesis of neurodegenerative diseases like temporal lobe epilepsy (TLE), the most common type of adult epilepsies (Beesley et al., 2020a). This review will outline pertinent ideas relating structure and function of t-NMDARs (GluN3 subunit-containing triheteromeric NMDARs) for which d-serine might serve as an inverse co-agonist. We will explore how tracing d-serine's origins blends glutamate-receptor biology with glial biology to help provide fresh perspectives on how neurodegeneration might interlink with neuroinflammation to initiate and perpetuate the disease state. Taken together, we envisage the review to deepen our understanding of endogenous d-serine's new role in the brain while also recognizing its therapeutic potential in the treatment of TLE that is oftentimes refractory to medications.

Identifiants

pubmed: 37437688
pii: S0028-3908(23)00244-7
doi: 10.1016/j.neuropharm.2023.109654
pii:
doi:

Substances chimiques

Receptors, N-Methyl-D-Aspartate 0
Serine 452VLY9402

Types de publication

Journal Article Review Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

109654

Informations de copyright

Copyright © 2023 The Authors. Published by Elsevier Ltd.. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests. Sanjay S. Kumar reports financial support was provided by National Institute of Neurological Disorders and Stroke.

Auteurs

Stephen Beesley (S)

Department of Biomedical Sciences, College of Medicine & Program in Neuroscience Florida State University, 1115 W. Call Street, Tallahassee, FL, 32306-4300, USA.

Sanjay S Kumar (SS)

Department of Biomedical Sciences, College of Medicine & Program in Neuroscience Florida State University, 1115 W. Call Street, Tallahassee, FL, 32306-4300, USA. Electronic address: sanjay.kumar@med.fsu.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH